Protease inhibitors and their peptidomimetic derivatives as potential drugs

Pharmacology and Therapeutics

Volumn 113, Issue 2, 2007, Pages 354-368

  Fear, Georgie ^a   Komarnytsky, Slavko ^a   Raskin, Ilya ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Approved drugs; Clinical trials; Protease; Protease inhibitors; Therapeutic application

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; AE 941; ALISKIREN; AMPRENAVIR; AMPRENAVIR PHOSPHATE; APROTININ; ATAZANAVIR; BENAZEPRIL; BRECANAVIR; CAPTOPRIL; CGS 27023A; DARUNAVIR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; INDINAVIR; LISINOPRIL; LOPINAVIR PLUS RITONAVIR; MOEXIPRIL; NELFINAVIR; OMAPATRILAT; PERINDOPRIL; PPL 100; PRALNACASAN; PRINOMASTAT; PROTEINASE INHIBITOR; PSN 9301; QUINAPRIL; RAMIPRIL; REBIMASTAT; RITONAVIR; RO 0334649; RUPINTRIVIR; SAQUINAVIR; SCH 503034; SITAGLIPTIN; TIPRANAVIR; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; VX 950;

ACCURACY; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; INFLAMMATION; OBESITY; PARASITOSIS; PNEUMONIA; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; VIRUS INFECTION;

ANIMALS; COMMUNICABLE DISEASES; DIABETES MELLITUS; FUNGI; HUMANS; INFLAMMATION; NEOPLASMS; PEPTIDES; PLANT EXTRACTS; PROTEASE INHIBITORS; VIRUSES;

EID: 33846415469     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.09.001     Document Type: Review

References (148)

1. Alexis N.E., Muhlebach M.S., Peden D.B., and Noah T.L. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros 5 (2006) 17-25
2. Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., and Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 21 (2002) 3213-3224
3. Arias C.F., Romero P., Alvarez V., and Lopez S. Trypsin activation pathway of rotavirus infectivity. J Virol 70 (1996) 5832-5839
4. Armstrong W.B., Kennedy A.R., Wan X.S., Taylor T.H., Nguyen Q.A., Jensen J., et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6 (2000) 4684-4691
5. Arribas J.R., Pulido F., Delgado R., Lorenzo A., Miralles P., Arranz A., et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 40 (2005) 280-287
6. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 5025-5037
7. Bacha U., Barrila J., Velazquez-Campoy A., Leavitt S.A., and Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43 (2004) 4906-4912
8. Baskin D.G., Lattemann D.F., Seeley R.J., Woods S.C., Porte D., and Schwartz M.W. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res 848 (1999) 114-123
9. Baum E.Z., Ding W.D., Siegel M.M., Hulmes J., Bebernitz G.A., Sridharan L., et al. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 35 (1996) 5847-5855
10. Bayes M., Rabasseda X., and Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 28 (2006) 31-63
11. Bectic J., Lell C.P., Fuchs A., Stoiber H., Speth C., Lass-Florl C., et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol Med Microbiol 31 (2001) 65-71
12. Bervar A., Zajc I., Sever N., Katunuma N., Sloane B.F., and Lah T.T. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem 384 (2003) 447-455
13. Bilfinger T.V., and Stefano G.B. The role of protease inhibition with emphasis on the effects of inflammation and vascular immune phenomena. Curr Pharm Des 8 (2002) 505-509
14. Billings P.C., Jin T., Ohnishi N., Liao D.C., and Habres J.M. The interaction of the potato-derived chymotrypsin inhibitor with C3H/10T1/2 cells. Carcinogenesis 12 (1991) 653-657
15. Binford S.L., Maldonado F., Brothers M.A., Weady P.T., Zalman L.S., Meador III J.W., et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49 (2005) 619-626
16. Blanco-Aparicio C., Molina M.A., Fernandez-Salas E., Frazier M.L., Mas J.M., Querol E., et al. Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J Biol Chem 273 (1998) 12370-12377
17. Bokarewa M., Dahlberg L., and Tarkowski A. Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis. Arthritis Res Ther 7 (2005) R1014-R1022
18. Bromme D., Klaus J.L., Okamoto K., Rasnick D., and Palmer J.T. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J 315 (1996) 85-89
19. Brown S., Meroueh S.O., Fridman R., and Mobashery S. Quest for selectivity in inhibition of matrix metalloproteinases. Curr Top Med Chem 4 (2004) 1227-1238
20. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20 (2006) 1341-1352
21. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 (2005) 407-419
22. Chen L., Gui C., Luo X., Yang Q., Gunther S., Scandella E., et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 79 (2005) 7095-7103
23. Chen Y.W., Huang S.C., Lin-Shiau S.Y., and Lin J.K. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 26 (2005) 1296-1306
24. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004) 252-256
25. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., and Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003) 2045-2046
26. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., and Doerr H.W. Treatment of SARS with human interferons. Lancet 362 (2003) 293-294
27. Conseil V., Soete M., and Dubremetz J.F. Serine protease inhibitors block invasion of host cells by Toxoplasma gondii. Antimicrob Agents Chemother 43 (1999) 1358-1361
28. Di Grandi M.J., Curran K.J., Baum E.Z., Bebernitz G., Ellestad G.A., Ding W.D., et al. Pyrimido[1,2-b]-1,2,4,5-tetrazin-6-ones as HCMV protease inhibitors: a new class of heterocycles with flavin-like redox properties. Bioorg Med Chem Lett 13 (2003) 3483-3486
29. Dumas J., Brittelli D., Chen J., Dixon B., Hatoum-Mokdad H., Konig G., et al. Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett 9 (1999) 2531-2536
30. Ebina T., and Tsukada K. Protease inhibitors prevent the development of human rotavirus-induced diarrhea in suckling mice. Microbiol Immunol 35 (1991) 583-588
31. Eriksson B.I., and Quinlan D.J. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 66 (2006) 1141-1429
32. Ersmark K., Samuelsson B., and Hallberg A. Plasmepsins as potential targets for new antimalarial therapy. Med Res Rev 26 (2006) 626-666
33. Evin G., Sernee M.F., and Masters C.L. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations, and strategies. CNS Drugs 20 (2006) 351-372
34. Fagan S.C., Hess D.C., Machado L.S., Hohnadel E.J., Pollock D.M., and Ergul A. Tactics for vascular protection after acute ischemic stroke. Pharmacotherapy 25 (2005) 387-395
35. Fujita M., Nakao Y., Matsunaga S., van Soest R.W.M., Itoh Y., Seiki M., et al. Callysponginol sulfate A, an MT1-MMP inhibitor isolated from the marine sponge Callyspongia truncata. J Nat Prod 66 (2003) 569-571
36. Gelhaus C., Vicik R., Schirmeister T., and Leippe M. Blocking effect of a biotinylated protease inhibitor on the egress of Plasmodium falciparum merozoites from infected red blood cells. Biol Chem 386 (2005) 499-502
37. Gladwell T.D. Bivalirudin: a direct thrombin inhibitor. Clin Ther 24 (2002) 38-58
38. Grant J., Dorward P.M., Buchan W.C., Armour J.C., and Pusztai A. Consumption of diets containing raw soya beans, kidney beans, cowpeas or lupin seeds by rats for up to 700 days: effects on body composition and organ weights. Br J Nutr 73 (1995) 17-29
39. Greenspan P.D., Clark K.L., Cowen S.D., McQuire L.W., Tommasi R.A., Farley D.L., et al. N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B. Bioorg Med Chem Lett 13 (2003) 4121-4124
40. Griese M., von Bredow C., Birrer P., and Schams A. Inhalation of alpha(1)-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity. Pulm Pharmacol Ther 14 (2001) 461-467
41. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 494 (2001) 192-195
42. Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47 (2003) 3907-3916
43. He R., Adonov A., Traykova-Adonova M., Cao J., Cutts T., Grudesky E., et al. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun 320 (2004) 1199-1203
44. Heath E.I., O'Reilly S., Humphrey R., Sundaresan P., Donehower R.C., Sartorius S., et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48 (2001) 269-274
45. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2001) 3071-3076
46. Hiemstra P.S. Novel roles of protease inhibitors in infection and inflammation. Biochem Soc Trans 30 (2002) 116-120
47. Hill A.J., Peikin S.R., Ryan C.A., and Blundell J.E. Oral administration of proteinase inhibitor II from potatoes reduces energy intake in men. Physiol Behav 48 (1990) 241-246
48. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
49. Hsyu P., Pithavala Y.K., Gersten M., Penning C.A., and Kerr B.M. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 46 (2002) 392-397
50. Hui D.Y. HIV protease inhibitors and atherosclerosis. J Clin Invest 111 (2003) 317-318
51. Ibrahim M.M. RAS inhibition in hypertension. J Hum Hypertens 20 (2006) 101-108
52. Jedinak A., and Maliar T. Inhibitors of proteases as anticancer drugs. Neoplasma 52 (2005) 185-192
53. Kaiser L., Crump C.E., and Hayden F.G. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 47 (2000) 215-220
54. Kakiuchi N., Komoda Y., Komoda K., Takeshita N., Okada S., Tani T., et al. Non-peptide inhibitors of HCV serine proteinase. FEBS Lett 421 (1998) 217-220
55. Katunuma N., Tsuge H., Nukatsuka M., and Fukushima M. Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis. Adv Enzyme Regul 42 (2002) 159-172
56. Katyal R., Rana S.V., Ojha S., Vaiphei K., Singh V., and Singh K. Soybean trypsin inhibitor confers protection against rotavirus infection in infant mice. Trop Gastroenterol 22 (2001) 207-210
57. Kennedy A.R., and Wan X.S. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50 (2002) 125-133
58. Kher A., Meldrum K.K., Hile K.L., Wang M., Tsai B.M., Turrentine M.W., et al. Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion. J Thorac Cardiovasc Surg 130 (2005) 662-669
59. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
60. Koblinski J.E., Ahram M., and Sloane B.F. Unraveling the role of proteases in cancer. Clin Chim Acta 291 (2000) 113-135
61. Kono K., Takahashi A., Sugai H., Umekawa T., Yano T., Kamiyasu, et al. Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg 190 (2005) 412-417
62. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003) 1953-1966
63. Kumar P.K., Machida K., Urvil P.T., Kakiuchi N., Vishnuvardhan D., Shimotohno K., et al. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237 (1997) 270-282
64. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
65. Lamparter S., Slight S.H., and Weber K.T. Doxycycline and tissue repair in rats. J Lab Clin Med 139 (2002) 295-302
66. Lapchak P.A., and Araujo D.M. Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 15 (2001) 819-829
67. Lapchak P.A., Chapman D.F., and Zivin J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31 (2000) 3034-3040
68. Lawrence P.K., and Koundal K.R. Plant protease inhibitors in the control of phytophagous insects. Electron J Biotechnol 5 (2002) (Accessed February 10, 2006)
69. Lee M., Fridman R., and Mobashery S. Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33 (2004) 401-409
70. Lewis E.J., Bishop J., Bottomley K.M., Bradshaw D., Brewster M., Broadhurst M.J., et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121 (1997) 540-546
71. Lin C.W., Tsai F.J., Tsai C.H., Lai C.C., Wan L., Ho T.Y., et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res 68 (2005) 36-42
72. Lin C., Kwong A.D., and Perni R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 6 (2006) 3-16
73. Liu G., Chen N., Kaji A., Bode A.M., Ryan C.A., and Dong Z. Proteinase inhibitors I and II from potatoes block UVB-induced AP-1 activity by regulating the AP-1 protein compositional patterns in JB6 cells. Proc Natl Acad Sci U S A 98 (2001) 5786-5791
74. Liu J., Sukhova G.K., Yang J.T., Sun J., Ma L., Ren A., et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 184 (2006) 302-311
75. Lobmann R., Schultz G., and Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care 28 (2005) 461-471
76. Low S.H., Wong S.H., Tang B.L., Subramaniam N., and Hong W. Apical cell surface expression of rat dipeptidyl peptidase IV in transfected Madin -Darby canine kidney cells. J Biol Chem 266 (1991) 13391-13396
77. Mackman R.L., Hui H.C., Breitenbucher J.G., Katz B.A., Luong C., Martelli A., et al. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg Med Chem Lett 12 (2002) 2019-2022
78. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 40 (1997) 2525-2532
79. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50 (2006) 1013-1020
80. Maliar T., Jedinak A., and Sturdik E. Rational screening of polyphenolic compounds as perspective trypsin like enzyme inhibitors. Chem Listy 96 (2002) 126-131
81. Martin F., Dimasi N., Volpari C., Perrera C., Di Marco S., Brunetti M., et al. Design of selective eglin inhibitors of HCV NS3 proteinase. Biochemistry 37 (1998) 11459-11468
82. Massova I., Kotra L.P., Fridman R., and Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12 (1998) 1075-1095
83. Matsumoto M., Misawa S., Chiba N., Takaku H., and Hayashi H. Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases. Biol Pharm Bull 24 (2001) 236-241
84. Matthews D.A., Patick A.K., Baker R.O., Brothers M.A., Dragovich P.S., Hartmann C.J., et al. In vitro antiviral activity of human rhinovirus 3C protease inhibitors against the SARS coronavirus. In: Knobler S., Mohmoud A., Lemon S., Mack A., Sivitz L., and Oberholtzer K. (Eds). Learning from SARS: Preparing for the Next Disease Outbreak (2002), The National Academies Press, Washington, DC 186-193
85. McIntosh C.H., Demuth H.U., Pospisilik J.A., and Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. Regul Pept 128 (2005) 159-165
86. Mikawa K., Akamatsu H., Maekawa N., Nishina K., Obara H., and Niwa Y. Acceleration of phagocytosis in human neutrophils incubated with gabexate mesilate. J Int Med Res 22 (1994) 292-295
87. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
88. Mohammed F.F., Smookler D.S., and Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum 62 (2003) ii43-ii47
89. Moran T.H. Cholecystokinin and satiety: current perspectives. Nutrition 16 (2000) 858-865
90. Mulligan M.S., Lentsch A.B., Huber-Lang M., Guo R.F., Sarma V., Wright C.D., et al. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol 156 (2000) 1033-1039
91. Murthy H.M., Judge K., DeLucas L., and Padmanabhan R. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: Implications for flaviviral polyprotein processing and drug design. J Mol Biol 301 (2000) 759-767
92. Nakatani K., Takeshita S., Tsujimoto H., Kawamura Y., and Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 69 (2001) 241-247
93. Noel A., Maillard C., Rocks N., Jost M., Chabottaux V., Sounni N.E., et al. Membrane associated proteases and their inhibitors in tumor angiogenesis. J Clin Pathol 57 (2004) 577-584
94. Nussberger J., Wuerzner G., Jensen C., and Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100). Hypertension 39 (2002) 1-8
95. Ogilvie W., Bailey M., Poupart M.A., Abraham A., Bhavsar A., Bonneau P., et al. Peptidomimetic inhibitors of the human cytomegalovirus protease. J Med Chem 40 (1997) 4113-4135
96. Oliva M.L., Souza-Pinto J.C., Batista I.F., Araujo M.S., Silveira V.F., Auerswald E.A., et al. Leucaena leucocephala serine proteinase inhibitor: primary structure and action on blood coagulation, kinin release and rat paw edema. Biochim Biophys Acta 1477 (2000) 64-74
97. Olson J.E., Lee G.K., Semenov A., and Rosenthal P.J. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg Med Chem 7 (1999) 633-638
98. Ottaviani J.I., Actis-Goretta L., Villordo J.J., and Fraga C.G. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition. Biochimie 88 (2005) 359-365
99. Overall C.M., and Kleifeld O. Tumour microenvironment- opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6 (2006) 227-239
100. Pan X., Tan N., Zeng G., Zhang Y., and Jia R. Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B. Bioorg Med Chem 13 (2005) 5819-5825
101. Patick A.K., and Potts K.E. Protease inhibitors as antiviral agents. Clin Microbiol Rev 11 (1998) 614-627
102. Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 43 (1999) 2444-2450
103. Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 49 (2005) 2267-2275
104. Peikin, S.R. (1985). Method of stimulating satiety in mammals. US Patent no 4,491,578.
105. Peikin S.R., Springer C.J., Dockray G.J., Blundell J.E., Hill A.J., Calam J., et al. Oral administration of proteinase inhibitor II from potatoes stimulates release of cholecystokinin in men. Gastroenterology 92 (1987) A1570-A1576
106. Pratley R.E., Jauffret-Kamel S., Galbreath E., and Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38 (2006) 423-428
107. Price A., Shi Q., Morris D., Wilcox M.E., Brasher P.M., Rewcastle N.B., et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5 (1999) 845-854
108. Rasmussen H.S., and McCann P.P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75 (1997) 69-75
109. Rawlings N.D., Tolle D.P., and Barrett A.J. Evolutionary families of peptidase inhibitors. Biochem J 378 (2004) 705-716
110. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
111. Reseland J.E., Holm H., Jacobsen M.B., Jenssen T.G., and Hanssen L.E. Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J Nutr 126 (1996) 634-642
112. Rockway T.W., and Giranda V.L. Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Des 9 (2003) 1483-1498
113. Rosenthal P.J. Cysteine proteases of malaria parasites. Int J Parasitol 34 (2004) 1489-1499
114. Sallenave J.M., Cunningham G.A., James R.M., McLachlan G., and Haslett C. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 71 (2003) 3766-3774
115. Schmid J., Kühn-Wache K., Rosche F., Wermann M., and Demuth H.U. Inhibiting prolyl endopeptidase and dipeptidyl peptidase IV by peptidyl pyridinium methyl ketones as substrate analog inhibitors. In: Bajusz S., and Hudecz F. (Eds). Peptides (1998) 840-841
116. Schwarcz S.K., Hsu L.C., Vittinghoff E., and Katz M.H. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am J Epidemiol 152 (2000) 178-185
117. Schwartz J.G., Guan D., Green G.M., and Phillips W.T. Treatment with an oral proteinase inhibitor slows gastric emptying and actually reduces glucose and insulin levels after a liquid meal in type II diabetic patients. Diabetes Care 17 (1994) 255-262
118. Selzer P.M., Pingel S., Hsieh I., Ugele B., Chan V.J., Engel J.C., et al. Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc Natl Acad Sci U S A 96 (1999) 11015-11022
119. Semenov A., Olson J.E., and Rosenthal P.J. Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother 42 (1998) 2254-2258
120. Senior K. Battle against malaria could involve anti-HIV drugs. Drug Discov Today 10 (2005) 1210
121. Seta T., Noguchi Y., Shimada T., Shikata S., and Fukui T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 16 (2004) 1287-1293
122. Shafren D.R., Gardner J., Mann V.H., Antalis T.M., and Suhrbier A. Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2. J Virol 73 (1999) 7193-7198
123. Shimoyama T., Tabuchi N., Kojima K., Akamatsu H., Arai H., Tanaka H., et al. Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18-hours preservation. Eur J Cardiothorac Surg 28 (2005) 581-587
124. Siemers E., Skinner M., Dean R.A., Gonzales C., Satterwhite J., Farlow M., et al. Effect of LY450139, a functional gamma-secretase inhibitor, on plasma and cerebrospinal fluid concentrations A-beta and cognitive functioning in patients with mild to moderate Alzheimer's disease. Neurology 62 (2004) A174
125. Soeparwata R., Hartman A.R., Frerichmann U., Stefano G.B., Scheld H.H., and Bilfinger T.V. Aprotinin diminishes inflammatory processes. Int J Cardiol 53 (1996) S55-S63
126. Sperl S., Mueller M.M., Wilhelm O.G., Schmitt M., Magdolen V., and Moroder L. The uPA/uPA receptor system as a target for tumor therapy. Drug News Perspect 14 (2001) 401-411
127. Sudo K., Matsumoto Y., Matsushima M., Fujiwara M., Konno K., Shimotohno K., et al. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem Biophys Res Commun 238 (1997) 643-647
128. Supuran C.T., Casini A., and Scozzafava A. Protease inhibitors of the sulfonamide type: anticancer, anti-inflammatory, and antiviral agents. Med Res Rev 23 (2003) 535-558
129. Tong L. Viral proteases. Chem Rev 102 (2002) 4609-4626
130. Tortorella M.D., Arner E.C., Hills R., Gormley J., Fok K., Pegg L., et al. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. Arch Biochem Biophys 444 (2005) 34-44
131. Towle M.J., Lee A., Maduakor E.C., Schwartz C.E., Bridges A.J., and Littlefield B.A. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 53 (1993) 2553-2559
132. Tsai K., Chen S., Liang P., Lu I., Mahindroo N., Hseih P., et al. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 49 (2006) 3485-3495
133. Wachtfogel Y.T., Bischoff R., Bauer R., Hack C.E., Nuijens J.H., Kucich U., et al. Alpha 1-antitrypsin Pittsburgh (Met358→Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation. Thromb Haemost 72 (1994) 843-847
134. Wachtfogel Y.T., Hack C.E., Nuijens J.H., Kettner C., Reilly T.M., Knabb R.M., et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 268 (1995) H1352-H1357
135. Wakselman M., Xie J., Mazaleyrat J.P., Boggetto N., Vilain A.C., Montagne J.J., et al. New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue. J Med Chem 36 (1993) 1539-1547
136. Wencker M., Fuhrmann B., Banik N., and Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 119 (2001) 737-744
137. Westfall E.J., and Hague S.M. The nutritive quality and trypsin inhibitor content of soybean flour heated at various temperatures. J Nutr 35 (1948) 374-380
138. Whittaker M., Floyd C.D., Brown P., and Gearing A.J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99 (1999) 2735-2776
139. Wieczerzak E., Drabik P., Lankiewicz L., Oldziej S., Grzonka Z., Abrahamson M., et al. Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem 45 (2002) 4202-4211
140. Witt H., Luck W., Hennies H.C., Classen M., Kage A., Lass U., et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 25 (2000) 213-216
141. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits Abeta production and alters lymphopoieseis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
142. Wood J.M., Maibaum J., Rahuel J., Grutter M.G., Cohen N.C., Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308 (2003) 698-705
143. Xiang J.S., Hu Y., Rush T.S., Thomason J.R., Ipek M., Sum P.E., et al. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett 16 (2006) 311-316
144. Yamamoto N., Yang R., Yoshinaka Y., Amari S., Nakano T., Cinatl J., et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 318 (2004) 719-725
145. Yavelow J., Collins M., Birk Y., Troll W., and Kennedy A.R. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc Natl Acad Sci U S A 82 (1985) 5395-5399
146. Zalman L.S., Brothers M.A., Dragovich P.S., Zhou R., Prins T.J., Worland S.T., et al. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 44 (2000) 1236-1241
147. Zhang K.E., Hee B., Lee C.A., Liang B., and Potts B.C. Liquid chromatography-mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease. Drug Metab Dispos 29 (2001) 729-734
148. Zhou L., Liu Y., Zhang W., Wei P., Huang C., Pei J., et al. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors. J Med Chem 49 (2006) 3440-3443